ResearcherNo recent work listed

Eramah Ermiah

ORCID-verified (high confidence)As of 14 November 2026

Matched on ORCID iD 0000-0002-8507-648X; OpenAlex author ID A5056592401.

Their work

Counts cover pancreatic cancer work only: a researcher’s other papers, trials and grants are not in these records.

Pancreatic cancer papers: 2 (first author 1, last author 1)
Pancreatic cancer trials: 0
Pancreatic cancer grants: 0
Collaborators: 2

Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper

Papers 2

Correlations of demographical and clinicopathological features with patient outcome of pancreatic ductal adenocarcinoma: A retrospective study (2010-2018) from… Last author DOI 10.4103/jcrt.jcrt_1778_21 ↗
Prognostic value of serum CEA and CA19-9 levels in pancreatic ductal adenocarcinoma. First author DOI 10.3892/mco.2022.2559 ↗

Closest collaborators

The 2 strongest of 2 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

Mona Mohamed Eddfair · 2 shared papers, 2022–2023
- Paper Correlations of demographical and clinicopathological features with patient outcome of pancreatic ductal adenocarcinoma… DOI 10.4103/jcrt.jcrt_1778_21 ↗
- Paper Prognostic value of serum CEA and CA19-9 levels in pancreatic ductal adenocarcinoma. DOI 10.3892/mco.2022.2559 ↗
Abdelbaset S Buhmeida · 2 shared papers, 2022–2023
- Paper Correlations of demographical and clinicopathological features with patient outcome of pancreatic ductal adenocarcinoma… DOI 10.4103/jcrt.jcrt_1778_21 ↗
- Paper Prognostic value of serum CEA and CA19-9 levels in pancreatic ductal adenocarcinoma. DOI 10.3892/mco.2022.2559 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.